TGF-β / Smad Signaling - PDGFR - RSK
The TGF-β family is generally classified into two sub-families, TGF-β ligands, and bone morphogenic protein (BMP) ligands. In canonical signaling, receptor activation lead to phosphorylation of a group of transcription factors called Smads. TGF-β ligands bind to type II receptors (TGF-β II) which recruit and phosphorylate type I receptor (TGF-β I) on serine/threonine residues. The TGF-β I then recruits and phosphorylates a receptor regulated Smad (R-Smad). The R-Smad binds to the common Smad (Co-Smad) and forms a heterodimeric complex. This complex then translocates into the cell nucleus where it binds with nuclear co-factors to regulate the transcription of various target genes. Dysregulation of TGF-β/Smad signaling pathway is associated with a number of pathological conditions including fibrosis, cancer, immunodeficiency, diabetes and cardiovascular diseases etc.
- B5954 Dasatinib Monohydrate中文名: 达沙替尼一水合物Target: PDGFR|c-Kit|Bcr-Abl|SrcSummary: ABL\SRC\KIT\PDGFR以及其它酪氨酸激酶抑制剂
- B3392 GSK269962ATarget: ROCK|RSK|MSKSummary: ROCK抑制剂
- A5467 Ponatinib (AP24534)1 Citation中文名: 帕纳替尼Target: VEGFR|PDGFR|Bcr-Abl|FGFR|SrcSummary: pan-BCR-ABL抑制剂,多激酶抑制剂
- A1805 Imatinib Mesylate (STI571)中文名: 甲磺酸伊马替尼Target: PDGFR|c-Kit|Bcr-AblSummary: Abl/c-kit/PDGFR抑制剂